ドライアイ症候群治療市場：製品タイプ別、流通チャネル別、地域別、2026～2032年

ドライアイ症候群治療市場の評価-2026～2032年

ドライアイ症候群の有病率の増加、特に高齢化とスクリーン利用者の増加が、ドライアイ症候群治療市場を押し上げています。Verified Market Researchのアナリストによると、ドライアイ症候群治療市場は、2024年に評価された約88億1,000万米ドルを下回り、2032年には227億1,000万米ドルの評価額に達すると推定されます。

ドライアイ症候群治療市場の急拡大は、効果的な治療法に対する世界の需要の高まりと、治療オプションの技術的進歩が主要因です。これにより、市場は2026～2032年にかけて13.86%のCAGRで成長することになります。

ドライアイ症候群治療市場定義/概要

ドライアイ症候群は、涙の分泌不足や涙の急激な蒸発を特徴とする疾患で、不快感や視力障害の可能性があります。ドライアイ症候群の治療法には、人工涙液、抗炎症薬、涙を節約したり涙の分泌を促進したりする処置などがあります。

さらに、ドライアイ症候群の治療には、症状の即時緩和、根本的な原因の管理、さらなる合併症の予防など、幅広い用途があります。防腐剤を含まない製剤や新しいドラッグデリバリーシステムなどの治療法の改良が、患者の予後を改善し、市場の成長を促進しています。

ドライアイ症候群治療市場の成長を促進する主要因は？

ドライアイ症状はますます一般的になっており、これが市場促進要因となっています。米国国立眼科ラボ（NEI）によると、米国では1,600万人以上の成人がDESと診断されており、さらに数百万人が未診断の可能性があるといいます。患者数の増加により、より効果的な治療の選択肢が求められています。

高齢化により、ドライアイ治療に対するニーズは非常に高まっています。世界保健機関（WHO）によると、2030年までに世界の6人に1人が60歳以上になるといいます。ドライアイ症状は高齢者に多いため、高齢化は市場拡大の原動力になると考えられます。

さらに、スクリーン使用時間の増加やデジタル眼精疲労がドライアイ治療の需要を促進しています。2020年に発表されたVision Councilの調査によると、アメリカ人の59%が長時間のスクリーン使用によりデジタル眼精疲労の症状を示しており、これはドライアイ症候群に直接関連しています。スクリーンを使用する時間が増えるにつれ、効果的な治療法の需要も増えています。

ドライアイ症候群治療の市場導入に影響を与える主要課題は？

ドライアイ症候群の画期的な治療には高額な費用がかかることが、その治療が受け入れられるための大きな障壁となっています。長期的な治療には、高価な処方薬、専門医による点眼薬、パンクチュアルプラグや熱脈動システムなどの医療機器が必要となります。ヘルスケアの適用範囲が限られていたり、自己負担額が高額であったりする地域の患者は、こうした価格のためにかなりの障壁に直面しています。患者は治療を遅らせたり、病気の管理に有益でない市販薬を使用したりします。

症状があっても、一時的な不快感や環境要因によるものだと勘違いし、医療機関を受診しない人も多いです。さらに、ヘルスケアプロバイダは、特に初期の段階では、ドライアイ症候群を重要な健康問題として必ずしも優先して考えていないです。このような認識や診断の欠如は、効果的な治療の導入を妨げます。患者は、この症状が慢性的なものであることや、生活の質を大幅に改善できる専門的な治療法があることに気づかないからです。

さらに、治療効果にばらつきがあることも、ドライアイ症候群の治療法導入の課題となっています。ドライアイ症候群には環境要因、ホルモンの変化、基礎疾患など複数の原因があるため、治療成績は患者によって大きく異なります。特定の治療法に反応しない患者もいれば、継続使用を躊躇させるような副作用を経験する患者もいます。このような治療効果の予測不可能性が、患者のフラストレーションを招き、配合された治療法のコンプライアンスを低下させ、状態を長期的に管理するためにデザインされた先進的な治療法の全体的な採用率を低下させました。

目次

第1章 世界のドライアイ症候群治療市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のドライアイ症候群治療市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 ドライアイ症候群治療の世界市場：製品タイプ別

• 概要
• 人工涙液
• 抗炎症薬
• 穿刺プラグ
• 分泌促進薬
• その他

第6章 ドライアイ症候群治療の世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 ドライアイ症候群治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のドライアイ症候群治療市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Novartis AG
• Allergan plc
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Akorn, Inc.
• Thea Pharmaceuticals Limited
• OASIS Medical

第10章 付録

• 関連調査

Dry Eye Syndrome Treatment Market Valuation - 2026-2032

The increasing prevalence of dry eye syndrome, particularly among the aging population and increased screen time users, is driving the Dry Eye Syndrome Treatment Market upwards. According to the analyst from Verified Market Research, the Dry Eye Syndrome Treatment Market is estimated to reach a valuation of USD 22.71 Billion in 2032, by subjugating around USD 8.81 Billion valued in 2024.

The rapid expansion of the Dry Eye Syndrome Treatment Market is primarily driven by the rising global demand for effective therapies, as well as technological advancements in treatment options. It enables the market to grow at a CAGR of 13.86% from 2026 to 2032.

Dry Eye Syndrome Treatment Market: Definition/ Overview

Dry eye syndrome is a condition characterized by insufficient tear production or rapid tear evaporation, leading to discomfort and potential vision problems. Treatment options for dry eye syndrome include artificial tears, anti-inflammatory medications, and procedures to conserve tears or stimulate tear production.

Furthermore, dry eye syndrome treatments have a wide range of applications, including providing immediate relief from symptoms, managing underlying causes, and preventing further complications. Improved treatments, such as preservative-free formulations and novel drug delivery systems, are enhancing patient outcomes and driving market growth.

What are the Key Drivers Propelling the Growth of the Dry Eye Syndrome Treatment Market?

Dry eye condition is becoming increasingly common, which is a major market driver. According to the National Eye Institute (NEI), more than 16 million adults in the United States have been diagnosed with DES, with millions more potentially undiagnosed. The growing patient population demands more effective treatment choices.

The aging population is greatly increasing the need for dry eye remedies. According to the World Health Organization (WHO, by 2030, one in every six persons worldwide would be 60 or older. Because dry eye conditions are more common among older persons, the aging population is likely to drive market expansion.

Furthermore, the increase in screen time and digital eye strain is driving demand for dry eye remedies. According to a Vision Council study published in 2020, 59% of American people express symptoms of digital eye strain because of prolonged screen use, which is directly linked to dry eye syndrome. As screen time increases, so does the demand for effective therapies.

What are the Key Challenges Impacting the Adoption of Dry Eye Syndrome Treatment in the Market?

The high expense of innovative treatments for dry eye syndrome is a major barrier to their acceptance. Long-term treatment requires expensive prescription medications, specialist eye drops, and medical devices such as punctual plugs or thermal pulsation systems. Patients in areas with limited healthcare coverage or high out-of-pocket charges face considerable barriers due to these prices. Patients delay therapy or use over-the-counter medicines, which are not beneficial for managing the illness.

Many individuals experiencing symptoms do not seek medical attention, mistaking their condition for temporary discomfort or attributing it to environmental factors. Furthermore, healthcare providers do not always prioritize dry eye syndrome as a significant health issue, especially in the early stages. This lack of awareness and diagnosis hinders the adoption of effective treatments, as patients do not realize the chronic nature of the condition or the availability of specialized therapies that could significantly improve their quality of life.

Furthermore, the variability in treatment effectiveness also poses a challenge in the adoption of dry eye syndrome treatments. Since dry eye syndrome has multiple causes, including environmental factors, hormonal changes, and underlying medical conditions, treatment outcomes vary greatly from one patient to another. Some patients do not respond well to certain therapies or experience side effects that discourage continued use. This unpredictability in treatment response led to patient frustration, reduced compliance with prescribed therapies, and lower overall adoption of advanced treatments designed to manage the condition long-term.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Artificial Tears?

According to VMR analysis, the artificial tears segment is estimated to dominate the market in the product type segment during the forecast period. Artificial tears provide immediate relief by lubricating the eyes and are widely available over the counter, making them highly accessible to patients. This widespread availability and ease of use contribute significantly to their market dominance.

Also, technological advancements have led to the development of preservative-free and long-lasting formulations of artificial tears. These innovations have enhanced the efficacy and safety profile of artificial tears, making them more appealing to both patients and healthcare providers. The improved formulations address concerns about preservative-related irritation and offer longer-lasting relief, further driving their popularity in the market.

Furthermore, artificial tears are often recommended as a first-line treatment for dry eye syndrome by eye care professionals. They are suitable for mild to moderate cases of dry eye and be used in conjunction with other treatments for more severe cases. This application's versatility contributes to their widespread use and market dominance.

What are the Potential Factors for the Growth of Retail Pharmacies in the Market?

The retail pharmacies segment is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. Retail pharmacies offer widespread accessibility and convenience for patients seeking over-the-counter dry eye treatments like artificial tears and lubricating eye drops. They are often the first point of contact for individuals looking for immediate relief from dry eye symptoms, contributing to their market dominance.

The growing number of chain pharmacies and drugstores has significantly expanded the reach of retail pharmacies. These establishments often offer a wide range of dry eye products, from basic artificial tears to more specialized treatments. The convenience of accessing these products alongside other healthcare needs makes retail pharmacies a preferred channel for many consumers.

Furthermore, many retail pharmacies now offer personalized in-store consultations with pharmacists. These consultations provide valuable guidance to customers in selecting appropriate dry eye treatments, enhancing the overall customer experience, and building trust. This personalized approach, combined with the immediate availability of products, strengthens the position of retail pharmacies in the Dry Eye Syndrome Treatment Market.

Country/Region-wise Acumens

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. North America, particularly the U.S., has a high prevalence of dry eye syndrome, driving the demand for treatment options. According to the American Academy of Ophthalmology, approximately 16 million people in the U.S. have been diagnosed with dry eye disease. This large patient population supports the region's dominance in the market for dry eye treatments.

North America benefits from strong research and development activities in the healthcare sector. This leads to innovative product launches and advanced treatment options for dry eye syndrome. The region's robust healthcare infrastructure and high awareness of eye health among the population further cement its market dominance.

Furthermore, the increasing use of digital devices and screen time, particularly in the U.S., has contributed to a rising number of dry eye cases. A report from the Vision Council revealed that nearly 80% of American adults use digital devices for more than two hours per day, which significantly increases the risk of developing dry eye. This growing trend is fueling the demand for effective treatments in North America.

How Do Demographic Shifts Shape the Market Landscape in the Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth rate within the Dry Eye Syndrome Treatment Market during the forecast period. The rapid urbanization and increasing pollution levels in Asia-Pacific are contributing to the rising prevalence of dry eye syndrome. A study published by the World Health Organization (WHO) highlighted that many major cities in Asia, such as New Delhi and Beijing, experience high levels of air pollution, which exacerbates eye health issues, including dry eye.

The aging population across many countries in the Asia-Pacific region is another significant driver for the Dry Eye Syndrome Treatment Market. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the number of people aged 60 or older in Asia-Pacific is expected to increase from 630 million in 2020 to 1.3 billion by 2050. As dry eye syndrome is more prevalent among older adults, this demographic shift is contributing to the growing demand for treatment solutions.

Furthermore, the rapid adoption of digital devices, particularly in countries like China, Japan, and India, is fueling the rise in dry eye syndrome cases. According to a report by the Indian Council of Medical Research (ICMR), more than 50% of Indian adults experience digital eye strain due to excessive screen time, leading to a higher prevalence of dry eye symptoms. This growing trend of digital device usage is significantly boosting the demand for dry eye treatments in the Asia-Pacific region.

Competitive Landscape

The Dry Eye Syndrome Treatment Market's competitive landscape is characterized by a diverse range of companies, including pharmaceutical giants, specialty eye care companies, and innovative startups, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the Dry Eye Syndrome Treatment Market include:

Novartis AG, Allergan plc, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Akorn, Inc., Thea Pharmaceuticals Limited, OASIS Medical.

Latest Developments

In May 2023, Bausch + Lomb acquired Blink Tears from Johnson & Johnson Vision. This acquisition strengthens Bausch + Lomb's over-the-counter eye care product portfolio, expanding its market reach in the dry eye treatment space.

In October 2022, Novartis received FDA approval for its Xiidra (lifitegrast ophthalmic solution) for the treatment of dry eye disease in patients 17 years and older. The approval enhances the company's stronghold in the growing dry eye market by offering a proven therapeutic solution.

Dry Eye Syndrome Treatment Market, By Category

• Product Type:
• Artificial Tears
• Anti-inflammatory Drugs
• Punctal Plugs
• Secretagogues
• Others
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Rest of the World

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DRY EYE SYNDROME TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DRY EYE SYNDROME TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Artificial Tears
• 5.3 Anti-inflammatory Drugs
• 5.4 Punctal Plugs
• 5.5 Secretagogues
• 5.6 Others

6 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL DRY EYE SYNDROME TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Novartis AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Allergan plc
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Bausch Health Companies Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Santen Pharmaceutical Co., Ltd.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Johnson & Johnson
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Otsuka Pharmaceutical Co., Ltd.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sun Pharmaceutical Industries Ltd.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Akorn, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Thea Pharmaceuticals Limited
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 OASIS Medical
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research